4. DHA‐P versus AS+MQ/AL6: QTc measurements.
| Study ID | No. of participants | Day | Outcome | Correction method | DHA‐P (%) | AS+MQ (%) | P value |
| Valecha 2010 AS | 1150 | At baseline | Borderline QTc (431 to 450ms) | QTcB | 16.6 | 12.1 | 0.066 |
| QTcF | 2.9 | 1.6 | >0.05 | ||||
| Day 2 | Borderline QTc (431 to 450ms) | QTcB | 21.4 | 16.3 | 0.043 | ||
| QTcF | 13.0 | 5.3 | <0.001 | ||||
| Prolonged QTc (> 450ms) | QTcB | 8.6 | 4.2 | 0.007 | |||
| QTcF | 4.7 | 5.3 | < 0.0011 | ||||
| QTc increase > 60 ms | QTcB | 0.9 | 0.8 | > 0.05 | |||
| QTcF | 4.6 | 2.9 | < 0.001 | ||||
| Day 7 | No differences between groups | N/R | N/R | > 0.05 | |||
| DHA‐P (%) | AL6 (%) | P value | |||||
| Bassat 2009 AF | 1553 | At baseline | Borderline QTc (431‐450ms) | N/R | N/R | ||
| Day 2 | Borderline QTc (431‐450ms) | QTcB | 29.1 | 19.8 | < 0.001 | ||
| QTcF | 1.0 | 1.2 | 0.76 | ||||
| Prolonged QTc (> 450ms) | QTcB | 9.1 | 6.9 | 0.152 | |||
| QTcF | 0.2 | 0.2 | 0.992 | ||||
| QTc > 500 ms | QTcB | 0.19 | 0.39 | > 0.05 | |||
| QTcF | N/R | N/R | |||||
| QTc increase > 60 ms | QTcB | 2.7 | 2.0 | > 0.05 | |||
| QTcF | N/R | N/R | |||||
| Day 7 | No differences between groups | N/R | N/R | > 0.05 | |||
1 In this analysis the direction of effect is reversed. These figures have been confirmed as correct by the study authors. 2 Figures not presented in paper: Taken from Analysis 4.13. N/R ‐ Not reported QTcB ‐ QT interval corrected for rate and gender using Bazett's method. QTcF ‐ Qt interval corrected for rate and gender using Fridericia's method.